MapleStory Expands Game Universe in Neo Part One Update With New Archer Class, Kain
10.6.2021 13:15:00 EEST | Business Wire | Press release
MapleStory , the iconic free-to-play global MMORPG from Nexon, has today launched Neo: Darkness Ascending, Part One of its summer update, the largest content update to the game in 2021. Neo Part One adds an all new area, Cernium, increases the max level to 300, and offers special limited-time events today, in addition to adding a new Nova Archer job, Kain, on June 23.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210610005162/en/
MAPLESTORY EXPANDS GAME UNIVERSE IN NEO PART ONE UPDATE WITH NEW ARCHER CLASS, KAIN (Graphic: Business Wire)
First, a new Nova Archer job – the Darkness Chaser, Kain – joins the game on June 23. Kain is a powerful archer, fighting to recover his lost past after discovering that his organization had deceived him. Using the Whispershot, a one-handed weapon, alongside melee weapons from his Weapon Belt, Kain commands an effective and versatile weapons mastery to inflict critical hits on his enemies.
The border between two worlds has disappeared and Cernium, City of the Gods, has reappeared. New area Cernium is now available in-game and brings new challenges and quests to all players. For an added boost, a special power called Sacred Power is now available to aid in the battle against monsters inhabiting the Grandis Continent. Sacred Power is acquired by equipping Sacred Symbols, which can be enhanced to increase Sacred Power as well as main stats.
Starting today, the maximum character level is increased from 275 to 300 and the amount of EXP required to level up between levels 210-250 has been reduced. The update also includes increased EXP rewards for Arcane River quests, and modifies the character death penalty to a decreased drop rate percentage instead of overall experience lost.
Part One of the Neo Update also brings the new Neo Castle event to MapleStory . Neo Castle, an area shrouded in mystery, was formed when Maple World and Grandis World combined, creating a space to enjoy a series of new events with the following features and shops available now:
- Neo Stone Shop: Players can exchange Neo Stones for a variety of improvements that can be used to enhance items and boost character growth
- Neo Gem Shop: Neo Gems are earned by playing one of the many new mini-games, and can be used to buy special cosmetic items
- Neo Core Shop: Neo Cores can be collected by battling bosses and can be used to purchase a variety of rare items
- Neo Meso Shop: The Meso shop is stocked full of powerful items that can be purchased using Mesos
The Neo Update also includes the following updates and features:
Burning World and Tera Burning
Burning World and Tera Burning events return to support speedy player growth, allowing players to create and designate burning characters who will gain 1+2 levels each time they level up, to Lv. 150 and Lv. 200 respectively, receive additional level-up rewards, and earn the 17-Star Unique Absolab weapon.
The Better Maple Project brings a host of new improvements for overall improved gameplay including:
- The V Matrix has been improved for easier use
- Boss Battles have been improved and a new boss entry system has been added, allowing players to move to the waiting area immediately from the current channel simply by selecting the boss, difficulty and pressing “GO”
- Skill Tooltips have been widened for better legibility and understanding of skill descriptions
- Equipped item functionality has been improved, allowing players the ability to compare equipped items with other items linked in chat
- The Clean Slate Scroll has been updated, and while in possession, is changed to a Pure Clean Slate Scroll to protect the item from being destroyed when it fails
- A Notification has been added to alert players when Safeguard is automatically disabled during Star Force enhancement
- Meso Market trades that are in progress for other characters in the same world have been updated and can be viewed in addition to canceling or receiving trades
- The Meso Market’s daily listing limit has been increased to 20
- Maplers can now purchase Mu Gong's Soul Shard from the Mu Lung Dojo Point Shop
To learn more about MapleStory , please visit http://maplestory.nexon.net
Social Media: TikTok / Twitter / Instagram / Twitch / Facebook / YouTube / Website
About MapleStory https://maplestory.nexon.net
MapleStory is one of the largest and most active free-to-play, side-scrolling MMORPGs with over 13 million registered players from its Global services alone out of a total seven MapleStory services around the world. First released in North America in May 2005, the game continues to grow and evolve alongside its passionate community since launching over 16 years ago. There have been over 274 million characters created to date, which would make MapleStory the 4th highest populated country in the world.
About Nexon America Inc. https://www.nexon.com/
Nexon America, a subsidiary of NEXON Co., Ltd. (“Nexon”) (3659.TO), is a global leader in online games, with more than 100 live games operated across more than 190 countries. Nexon pioneered micro-transactions and the free-to-play business model, and is widely credited with unmatched global expertise in sophisticated live game operations, nurturing player communities, and for sustaining titles for years, even decades. Founded in Korea in 1994, the company is now headquartered in Japan and listed on the Tokyo Stock Exchange.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210610005162/en/
Contact information
Nexon America
Yoonmi Park
yopark@nexon.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
